IGF1R and non-small cell lung carcinoma: Furthermore, the addition of h7C10, anti-IGF-1R monoclonal antibody (mAB), to cetuximab, EGFR mAB, in A549 non-small cell lung cancer (NSCLC) xenograft models of wild-type EGFR and activated RAS mutation led to growth inhibition, unlike cetuximab alone [14].